

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](https://fdi-lab.org) on Apr 3, 2025

TCCSUP

RRID:CVCL_1738

Type: Cell Line

Proper Citation

(RRID:CVCL_1738)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1738

Proper Citation: (RRID:CVCL_1738)

Sex: Female

Defining Citation: [PMID:571047](#), [PMID:836756](#), [PMID:3518877](#), [PMID:3708594](#), [PMID:6220172](#), [PMID:6244232](#), [PMID:6582512](#), [PMID:6823318](#), [PMID:6826254](#), [PMID:7787250](#), [PMID:9850064](#), [PMID:11416159](#), [PMID:11668190](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24018021](#), [PMID:24035680](#), [PMID:24367658](#), [PMID:25984343](#), [PMID:25997541](#), [PMID:26055179](#), [PMID:27270441](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:29732388](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: shRNA library screening., Omics: Protein expression by reverse-phase protein arrays., Omics: DNA methylation analysis., Omics: Deep quantitative proteome analysis., Omics: Deep exome analysis., Omics: CNV analysis., Population: Caucasian., Part of: UBC-40 urothelial bladder cancer cell line index., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BLA-40 bladder carcinoma cell line panel.

Category: Cancer cell line

Name: TCCSUP

Synonyms: TCCSuP, TCC-SUP, TCC Sup

Cross References: BTO:BTO_0006308, CLO:CLO_0009283, ArrayExpress:E-MTAB-783,

ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-5, BioGRID_ORCS_Cell_line:450, BioSample:SAMN03472747, BioSample:SAMN03473325, BioSample:SAMN10988046, cancercellines:CVCL_1738, CCRID:3101HUMSCSP571, Cell_Model_Passport:SIDM01190, ChEMBL-Cells:ChEMBL3307466, ChEMBL-Targets:ChEMBL615010, CLS:305073, Cosmic:687459, Cosmic:755398, Cosmic:925833, Cosmic:943734, Cosmic:1046692, Cosmic:1285131, Cosmic:1286003, Cosmic:2037961, Cosmic:2050466, Cosmic:2057460, Cosmic:2444246, Cosmic:2685942, Cosmic-CLP:687459, DepMap:ACH-000720, DSMZ:ACC-377, DSMZCellDive:ACC-377, EGA:EGAS00001000978, GDSC:687459, GEO:GSM136227, GEO:GSM142308, GEO:GSM142311, GEO:GSM142312, GEO:GSM827282, GEO:GSM888783, GEO:GSM1374955, GEO:GSM1374956, GEO:GSM1574563, GEO:GSM1670526, IARC_TP53:3724, LiGeA:CCL_887, LINC_SDP:LCL-1720, PharmacDB:TCCSUP_1570_2019, PRIDE:PXD030304, Progenetix:CVCL_1738, PubChem_Cell_line:CVCL_1738, Wikidata:Q54971867

ID: CVCL_1738

Record Creation Time: 20250131T202751+0000

Record Last Update: 20250131T204733+0000

Ratings and Alerts

No rating or validation information has been found for TCCSUP.

No alerts have been found for TCCSUP.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Hernández-Prat A, et al. (2024) Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors. *Molecular oncology*.

Klümper N, et al. (2023) PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma. *Oncoimmunology*, 12(1), 2267744.

Wang Y, et al. (2022) Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer. *Cancer research*, 82(6), 1128.

Athans S, et al. (2022) STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancer. *Cancer research communications*, 2(10), 1129.

Lu YT, et al. (2022) FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer. *Cancers*, 14(7).

Fu G, et al. (2022) Activation of cGAS-STING Signal to Inhibit the Proliferation of Bladder Cancer: The Immune Effect of Cisplatin. *Cells*, 11(19).

Vanoni G, et al. (2021) Human primed ILCPs support endothelial activation through NF- κ B signaling. *eLife*, 10.

Jiang G, et al. (2021) The Clinical Implications and Molecular Mechanism of CX3CL1 Expression in Urothelial Bladder Cancer. *Frontiers in oncology*, 11, 752860.

Wang L, et al. (2021) Immunosuppression Induced by Glutamine Deprivation Occurs via Activating PD-L1 Transcription in Bladder Cancer. *Frontiers in molecular biosciences*, 8, 687305.

Moose DL, et al. (2020) Cancer Cells Resist Mechanical Destruction in Circulation via RhoA/Actomyosin-Dependent Mechano-Adaptation. *Cell reports*, 30(11), 3864.

Kim S, et al. (2019) Epigenetic regulation of mammalian Hedgehog signaling to the stroma determines the molecular subtype of bladder cancer. *eLife*, 8.

Buj R, et al. (2019) Suppression of p16 Induces mTORC1-Mediated Nucleotide Metabolic Reprogramming. *Cell reports*, 28(8), 1971.

Chen JC, et al. (2018) IKZF1 Enhances Immune Infiltrate Recruitment in Solid Tumors and Susceptibility to Immunotherapy. *Cell systems*, 7(1), 92.